BriaCell Therapeutics Corp.
BCTX · NASDAQ
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | 0.08 | 0.15 |
| FCF Yield | -37.18% | -79.72% | -12.13% | -6.31% |
| EV / EBITDA | -2.17 | -0.32 | -7.54 | -14.09 |
| Quality | ||||
| ROIC | -85.30% | -66.29% | -51.43% | -169.56% |
| Gross Margin | 0.00% | -16.17% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.94 | 1.01 | 1.16 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 31.23% | -10.88% | -18.17% | 9.84% |
| Safety | ||||
| Net Debt / EBITDA | 0.33 | 0.94 | 1.96 | 0.81 |
| Interest Coverage | 0.00 | 0.00 | -171.13 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -7,260.41 | -7,870.75 | -10,752.32 | -17,283.18 |